FDA’s New Neonatology Panel To Discuss Challenges In Study Design, Conduct
This article was originally published in The Pink Sheet Daily
Discussion by the Pediatric Advisory Committee’s new subcommittee at a March 15 meeting will aid the agency’s development of a strategic plan for advancing neonatal science; FDA also is looking to outside contractors for help in meeting a FDASIA mandate to bolster neonatology expertise and encourage studies.
You may also be interested in...
Advocates for the agency worry that while each of the performance assessments seems reasonable individually, together the reports could burden staff to the point of pulling some from application reviews or other tasks to help complete them.
Advisory committee votes 24-2 against approval of Intellipharmaceutics’ Aximris XR due to concerns the extended-release oxycodone formulation may be more susceptible to intranasal abuse than existing products; Esteve fares better with its tramadol/celecoxib combination, securing a tie vote on approval for acute pain.
Although abuse by intravenous route is expected to be deterred compared to immediate-release oxycodone, neither nasal nor oral abuse deterrence was demonstrated in two new human abuse potential studies, agency concludes; product has a new formulation and a new name, Aximris XR, since a 2017 AdComm.